Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BPTH NASDAQ:CDT NASDAQ:INDP NASDAQ:SHPH On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBPTHBio-Path$0.06-9.0%$0.13$0.06▼$3.39$522K-0.03177,133 shs229,730 shsCDTCDT Equity$0.60$1.71$0.57▼$274.80$1.84M1.922.24 million shs1.08 million shsINDPIndaptus Therapeutics$2.58-8.8%$8.03$2.34▼$58.24$2.86M1.2782,073 shs1.94 million shsSHPHShuttle Pharmaceuticals$3.59+3.2%$3.64$3.00▼$56.25$3.73M-1.0823,554 shs93,111 shsMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBPTHBio-Path0.00%-47.67%-54.33%-66.52%-93.53%CDTCDT Equity0.00%-49.15%-64.07%-74.25%-99.72%INDPIndaptus Therapeutics0.00%-21.82%-66.97%-71.63%-94.02%SHPHShuttle Pharmaceuticals0.00%+6.37%+2.57%+2,603.31%-90.03%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBPTHBio-Path$0.06-9.0%$0.13$0.06▼$3.39$522K-0.03177,133 shs229,730 shsCDTCDT Equity$0.60$1.71$0.57▼$274.80$1.84M1.922.24 million shs1.08 million shsINDPIndaptus Therapeutics$2.58-8.8%$8.03$2.34▼$58.24$2.86M1.2782,073 shs1.94 million shsSHPHShuttle Pharmaceuticals$3.59+3.2%$3.64$3.00▼$56.25$3.73M-1.0823,554 shs93,111 shsMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBPTHBio-Path0.00%-47.67%-54.33%-66.52%-93.53%CDTCDT Equity0.00%-49.15%-64.07%-74.25%-99.72%INDPIndaptus Therapeutics0.00%-21.82%-66.97%-71.63%-94.02%SHPHShuttle Pharmaceuticals0.00%+6.37%+2.57%+2,603.31%-90.03%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBPTHBio-Path 0.00N/AN/AN/ACDTCDT Equity 0.00N/AN/AN/AINDPIndaptus Therapeutics 3.00Buy$238.009,124.81% UpsideSHPHShuttle Pharmaceuticals 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownCompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBPTHBio-PathN/AN/AN/AN/A$0.71 per shareN/ACDTCDT EquityN/AN/AN/AN/A($73.54) per shareN/AINDPIndaptus TherapeuticsN/AN/AN/AN/A$10.84 per shareN/ASHPHShuttle PharmaceuticalsN/AN/AN/AN/A$4.35 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBPTHBio-Path-$16.08MN/A0.00N/AN/AN/A-2,842.40%-337.48%11/13/2025 (Estimated)CDTCDT Equity-$17.80M-$435.00N/A∞N/AN/AN/A-350.23%11/12/2025 (Estimated)INDPIndaptus Therapeutics-$15.02M-$37.66N/AN/AN/AN/A-612.59%-243.78%N/ASHPHShuttle Pharmaceuticals-$9.15M-$4.15N/A∞N/AN/A-772.76%-347.06%N/ALatest BPTH, INDP, CDT, and SHPH EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q2 2025CDTCDT EquityN/A-$5.46N/A-$5.46N/AN/A8/13/2025Q2 2025INDPIndaptus Therapeutics-$0.36-$9.09-$8.73-$9.09N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBPTHBio-PathN/AN/AN/AN/AN/ACDTCDT EquityN/AN/AN/AN/AN/AINDPIndaptus TherapeuticsN/AN/AN/AN/AN/ASHPHShuttle PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBPTHBio-PathN/A0.860.86CDTCDT EquityN/A1.451.45INDPIndaptus TherapeuticsN/A0.750.75SHPHShuttle PharmaceuticalsN/A3.073.07Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBPTHBio-Path5.74%CDTCDT Equity3.29%INDPIndaptus Therapeutics7.06%SHPHShuttle Pharmaceuticals4.58%Insider OwnershipCompanyInsider OwnershipBPTHBio-Path0.72%CDTCDT Equity7.72%INDPIndaptus Therapeutics20.80%SHPHShuttle Pharmaceuticals12.60%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBPTHBio-Path108.31 million5.73 millionOptionableCDTCDT Equity33.06 million2.83 millionNot OptionableINDPIndaptus Therapeutics61.11 million877,000Not OptionableSHPHShuttle Pharmaceuticals51.07 million936,000Not OptionableBPTH, INDP, CDT, and SHPH HeadlinesRecent News About These CompaniesShuttle Pharmaceuticals Appoints Adam Chambers as DirectorSeptember 8, 2025 | tipranks.comShuttle Pharmaceuticals Director Steven Richards ResignsSeptember 5, 2025 | tipranks.comShuttle Pharmaceuticals Holdings, Inc.: Shuttle Pharma Provides Second Quarter 2025 Corporate UpdateAugust 16, 2025 | finanznachrichten.deShuttle Pharma Provides Second Quarter 2025 Corporate UpdateAugust 14, 2025 | globenewswire.comShuttle Pharmaceuticals COO Resigns Amid Leadership ChangesJuly 30, 2025 | tipranks.comShuttle Pharmaceuticals Inc News (SHPH) - Investing.comJuly 2, 2025 | investing.comSHPH - Shuttle Pharmaceuticals Holdings Inc Key Metrics | MorningstarJune 28, 2025 | morningstar.comMShuttle Pharmaceuticals Announces Closing of $4.25 Million Private Placement Priced At-the-Market - MorningstarJune 26, 2025 | morningstar.comMSHPH - Shuttle Pharmaceuticals Holdings Inc News | MorningstarJune 26, 2025 | morningstar.comMShuttle Pharmaceuticals Secures $4.25M in Private PlacementJune 26, 2025 | msn.comShuttle Pharmaceuticals Announces Closing of $4.25 Million Private Placement Priced At-the-MarketJune 24, 2025 | globenewswire.comShuttle Pharmaceuticals Announces Pricing of $4.25 Million Private Placement Priced At-the-MarketJune 20, 2025 | globenewswire.comShuttle Pharmaceuticals Holdings Inc trading halted, news pendingJune 14, 2025 | msn.comShuttle Pharmaceuticals says reverse stock split to become effective June 16June 13, 2025 | finance.yahoo.comShuttle Pharma Announces Reverse Stock Split will Become Effective on June 16, 2025, at 12:01 a.m., Eastern TimeJune 12, 2025 | globenewswire.comShuttle Pharmaceuticals Holdings, Inc. Proposes 25-for-1 Reverse Stock Split to Comply with Nasdaq RequirementsJune 12, 2025 | quiverquant.comQShuttle Pharma Announces Proposed Reverse Stock Split as Part of Strategic Nasdaq Compliance InitiativeJune 12, 2025 | globenewswire.comShuttle Pharma Appoints George Scorsis Chairman of the Board of DirectorsJune 4, 2025 | globenewswire.comShuttle Pharmaceuticals slashes exec salaries by 70% as it fights to preserve cashMay 29, 2025 | bizjournals.comShuttle Pharmaceuticals Holdings, Inc.: Shuttle Pharma Provides Corporate UpdateMay 16, 2025 | finanznachrichten.deNew MarketBeat Followers Over TimeMedia Sentiment Over TimeBPTH, INDP, CDT, and SHPH Company DescriptionsBio-Path NASDAQ:BPTH$0.06 -0.01 (-8.99%) As of 09/12/2025 03:59 PM EasternBio-Path Holdings, Inc. operates as a clinical and preclinical stage oncology focused RNAi nanoparticle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction. Its lead drug candidate is prexigebersen, which is in Phase II clinical trials for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome. It is also developing BP1001-A that is in Phase I clinical trial for the treatment of solid tumors; Liposomal Bcl-2 (BP1002), which is in Phase I clinical trial for the treatment of refractory/relapsed lymphoma and chronic lymphocytic leukemia; and Liposomal STAT3 (BP1003) for treating pancreatic cancer, non-small cell lung cancer, and AML. The company was founded in 2007 and is based in Bellaire, Texas.CDT Equity NASDAQ:CDT$0.60 0.00 (0.00%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$0.61 +0.01 (+1.83%) As of 09/12/2025 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Conduit Pharmaceuticals Inc., a clinical-stage specialty biopharmaceutical company, develops pharmaceutical products that provides unmet medical needs in the areas of autoimmune diseases and idiopathic male infertility. Its pipeline includes AZD1656, which has completed Phase I trials for the treatment of type 2 diabetes, renal transplant, Hashimoto's thyroiditis and Grave's disease, uveitis, and preterm labor; and AZD5904, which has completed Phase I clinical trials for the treatment of idiopathic male infertility. The company was founded in 2019 and is based in San Diego, California. Conduit Pharmaceuticals Limited is a subsidiary of Corvus Capital Limited.Indaptus Therapeutics NASDAQ:INDP$2.58 -0.25 (-8.83%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$2.42 -0.17 (-6.40%) As of 09/12/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Indaptus Therapeutics, Inc., a clinical biotechnology company, develops various anti-cancer and anti-viral immunotherapy products. Its lead clinical candidate is Decoy20 used to produce single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, and chronic hepatitis B virus, and human immunodeficiency virus infection, which is in Phase 2 clinical trial. The company was formerly known as Intec Parent, Inc. and changed its name to Indaptus Therapeutics, Inc. in August 2021. Indaptus Therapeutics, Inc. is headquartered in New York, New York.Shuttle Pharmaceuticals NASDAQ:SHPH$3.59 +0.11 (+3.16%) Closing price 09/12/2025 03:59 PM EasternExtended Trading$3.49 -0.10 (-2.79%) As of 09/12/2025 05:42 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Shuttle Pharmaceuticals Holdings, Inc., a clinical stage pharmaceutical company, develops novel therapies to cure cancers. It develops Ropidoxuridine, an oral halogenated pyrimidine to treat patients with brain tumors and sarcomas SP-1-161, an HDAC inhibitor that initiates the mutated in ataxia-telangiectasia response pathway for radiation sensitizing cancer cells and protecting normal cells; SP-2-225, a pre-clinical class IIb that effects on the regulation of the immune system; and SP-1-303, a pre-clinical selective Class I HDAC for the treatment of ER positive cancers . The company is based in Gaithersburg, Maryland. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 09/08 - 09/12 Meta's $600B U.S. Investment: Bearish or Bullish for Shares? Football Season Is Here and DraftKings Stock Is Surging RH Stock Slides After Mixed Earnings and Tariff Concerns Post Onum Deal: Is CrowdStrike Ready to Rebound After 16% Drop? Chewy’s September Pullback: Is It Your Time to Buy? It’s Time to Buy the Dip in Kroger Stock Price Is Coupang the Next MercadoLibre? A Playbook for Global Dominance Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
